Navoximod

• Description :

  Navoximod (GDC-0919; NLG- 919) is a potent IDO (indoleamine- (2,3) -dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.

• CAS Number :

  [1402837-78-8]

• Product Name Alternative :

  GDC-0919; NLG-​919

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319

• Target :

  Indoleamine 2,3-Dioxygenase (IDO)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Navoximod.html

• Purity :

  99.99

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3

• Molecular Formula :

  C18H21FN2O2

• Molecular Weight :

  316.37

• Precautions :

  H315, H319

• References & Citations :

  [1]Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO) -pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.|[2]Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.|[3]Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  IDO